「同位素标记抑制剂」CAS:142741-60-4|Tenidap-d3
【产品介绍】:
生物活性:Tenidap-d3 is the deuterium labeled Tenidap. Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties[1][2]. Tenidap is also a specific SLC26A3 inhibitor[3].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Tenidap-d3 相关抗体:
COX2 Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
COX IV Antibody (YA867)
Cyclooxygenase 1 Antibody (YA2537)
Cyclooxygenase 2 Antibody (YA2541)
分子量:323.77
Formula:C14H6D3ClN2O3S
CAS 号:142741-60-4
非标记 CAS:120210-48-2
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (533 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. Kirchner T, et al. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.
[Content Brief]
[3]. Blackburn WD Jr, et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum. 1995 Oct;38(10):1447-56.
[Content Brief]
[4]. Julio C Chávez, et al. Participation of the Cl-/HCO(3)- exchangers SLC26A3 and SLC26A6, the Cl- channel CFTR, and the regulatory factor SLC9A3R1 in mouse sperm capacitation. Biol Reprod. 2012 Jan 19;86(1):1-14.
[Content Brief]